Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro's vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants.
↧